Compare BLTE & OR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | OR |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 2021 | 2014 |
| Metric | BLTE | OR |
|---|---|---|
| Price | $129.67 | $30.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $233.00 | $43.50 |
| AVG Volume (30 Days) | 142.0K | ★ 881.9K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | ★ 0.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.08 |
| Revenue Next Year | N/A | $15.55 |
| P/E Ratio | ★ N/A | $55.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $115.41 | $27.54 |
| 52 Week High | $200.00 | $48.06 |
| Indicator | BLTE | OR |
|---|---|---|
| Relative Strength Index (RSI) | 32.18 | 34.80 |
| Support Level | N/A | $27.54 |
| Resistance Level | $158.76 | $37.28 |
| Average True Range (ATR) | 9.11 | 1.28 |
| MACD | -1.46 | -0.45 |
| Stochastic Oscillator | 19.04 | 2.13 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.